Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 8692

1.

Neoadjuvant Chemotherapy With Nab-paclitaxel Plus Trastuzumab Followed by 5-Fluorouracil/Epirubicin/Cyclophosphamide for HER2-positive Operable Breast Cancer: A Multicenter Phase II Trial.

Tokunaga S, Takashima T, Kashiwagi S, Noda S, Kawajiri H, Tokumoto M, Nishimura S, Nishimori T, Ikeda K, Ogawa Y, Mizuyama Y, Sunami T, Tezuka K, Yamagata S, Ishikawa T, Kudoh S, Takada M, Hirakawa K, Ohira M.

Anticancer Res. 2019 Apr;39(4):2053-2059. doi: 10.21873/anticanres.13316.

PMID:
30952749
2.

Serum platelet factor 4 is a promising predictor in newly diagnosed patients with multiple myeloma treated with thalidomide and VAD regimens.

Bai J, Wang J, Yang Y, Zhang W, Wang F, Zhang L, Chen H, Wang X, Feng Y, Shen Y, Huang L, He A.

Hematology. 2019 Dec;24(1):387-391. doi: 10.1080/16078454.2019.1592826.

PMID:
30890040
3.

Randomized phase 3 efficacy and safety trial of proposed pegfilgrastim biosimilar MYL-1401H in the prophylactic treatment of chemotherapy-induced neutropenia.

Waller CF, Ranganna GM, Pennella EJ, Blakeley C, Bronchud MH, Mattano LA Jr, Berzoy O, Voitko N, Shparyk Y, Lytvyn I, Rusyn A, Popov V, Láng I, Beckmann K, Sharma R, Baczkowski M, Kothekar M, Barve A.

Ann Hematol. 2019 May;98(5):1217-1224. doi: 10.1007/s00277-019-03639-5. Epub 2019 Mar 1.

4.

Addition of Zoledronate to Chemotherapy in Patients with Osteosarcoma Treated with Limb-Sparing Surgery: A Phase III Clinical Trial.

Li S, Chen P, Pei Y, Zheng K, Wang W, Qiu E, Zhang X.

Med Sci Monit. 2019 Feb 23;25:1429-1438. doi: 10.12659/MSM.913236.

5.

The Effect of Supplementary Omegaven® on the Clinical Outcome of Patients With Advanced Esophagogastric Adenocarcinoma Receiving Palliative Epirubicin, Oxaliplatin, and Capecitabine Chemotherapy: A Phase II clinical trial.

Eltweri AM, Thomas AL, Chung WY, Morgan B, Thompson J, Dennison AR, Bowrey DJ.

Anticancer Res. 2019 Feb;39(2):853-861. doi: 10.21873/anticanres.13185.

PMID:
30711967
6.

Prognostic Significance of Pretreatment Neutrophil/Lymphocyte Ratio and Platelet/Lymphocyte Ratio in Patients with Diffuse Large B-Cell Lymphoma.

Wang S, Ma Y, Sun L, Shi Y, Jiang S, Yu K, Zhou S.

Biomed Res Int. 2018 Dec 12;2018:9651254. doi: 10.1155/2018/9651254. eCollection 2018.

7.

Six versus eight doses of rituximab in patients with aggressive B cell lymphoma receiving six cycles of CHOP: results from the "Positron Emission Tomography-Guided Therapy of Aggressive Non-Hodgkin Lymphomas" (PETAL) trial.

Hüttmann A, Rekowski J, Müller SP, Hertenstein B, Franzius C, Mesters R, Weckesser M, Kroschinsky F, Kotzerke J, Ganser A, Bengel FM, La Rosée P, Freesmeyer M, Höffkes HG, Hertel A, Behringer D, Prange-Krex G, Griesshammer M, Holzinger J, Wilop S, Krohn T, Raghavachar A, Maschmeyer G, Brink I, Schroers R, Gaska T, Bernhard H, Giagounidis A, Schütte J, Dienst A, Hautzel H, Naumann R, Klein A, Hahn D, Pöpperl G, Grube M, Marienhagen J, Schwarzer A, Kurch L, Höhler T, Steiniger H, Nückel H, Südhoff T, Römer W, Brinkmann M, Ose C, Alashkar F, Schmitz C, Dürig J, Hoelzer D, Jöckel KH, Klapper W, Dührsen U.

Ann Hematol. 2019 Apr;98(4):897-907. doi: 10.1007/s00277-018-3578-0. Epub 2019 Jan 4.

PMID:
30610279
8.

Prophylactic use of carvedilol to prevent ventricular dysfunction in patients with cancer treated with doxorubicin.

Abuosa AM, Elshiekh AH, Qureshi K, Abrar MB, Kholeif MA, Kinsara AJ, Andejani A, Ahmed AH, Cleland JGF.

Indian Heart J. 2018 Dec;70 Suppl 3:S96-S100. doi: 10.1016/j.ihj.2018.06.011. Epub 2018 Jun 18.

9.

Randomized phase II study of the PDGFRα antibody olaratumab plus liposomal doxorubicin versus liposomal doxorubicin alone in patients with platinum-refractory or platinum-resistant advanced ovarian cancer.

McGuire WP, Penson RT, Gore M, Herraez AC, Peterson P, Shahir A, Ilaria R Jr.

BMC Cancer. 2018 Dec 27;18(1):1292. doi: 10.1186/s12885-018-5198-4.

10.

Brentuximab vedotin with chemotherapy for CD30-positive peripheral T-cell lymphoma (ECHELON-2): a global, double-blind, randomised, phase 3 trial.

Horwitz S, O'Connor OA, Pro B, Illidge T, Fanale M, Advani R, Bartlett NL, Christensen JH, Morschhauser F, Domingo-Domenech E, Rossi G, Kim WS, Feldman T, Lennard A, Belada D, Illés Á, Tobinai K, Tsukasaki K, Yeh SP, Shustov A, Hüttmann A, Savage KJ, Yuen S, Iyer S, Zinzani PL, Hua Z, Little M, Rao S, Woolery J, Manley T, Trümper L; ECHELON-2 Study Group.

Lancet. 2019 Jan 19;393(10168):229-240. doi: 10.1016/S0140-6736(18)32984-2. Epub 2018 Dec 4. Erratum in: Lancet. 2019 Jan 19;393(10168):228.

PMID:
30522922
11.

Evaluation of the effects of intra-arterial chemotherapy combined with intravesical chemotherapy against intravesical chemotherapy alone after transurethral resection of bladder tumor in T1-staged Grade 3 bladder cancer.

Huang B, Wang H, Lin H, Yao Z, Zheng J, Fan W, Qiu S, Chen L, Chen J.

J Cancer Res Clin Oncol. 2019 Feb;145(2):487-494. doi: 10.1007/s00432-018-2811-5. Epub 2018 Dec 11.

PMID:
30539282
12.

Combination of hyper-CVAD with ponatinib as first-line therapy for patients with Philadelphia chromosome-positive acute lymphoblastic leukaemia: long-term follow-up of a single-centre, phase 2 study.

Jabbour E, Short NJ, Ravandi F, Huang X, Daver N, DiNardo CD, Konopleva M, Pemmaraju N, Wierda W, Garcia-Manero G, Sasaki K, Cortes J, Garris R, Khoury JD, Jorgensen J, Jain N, Alvarez J, O'Brien S, Kantarjian H.

Lancet Haematol. 2018 Dec;5(12):e618-e627. doi: 10.1016/S2352-3026(18)30176-5.

PMID:
30501869
13.

Dose-adjusted EPOCH-R (etoposide, prednisone, vincristine, cyclophosphamide, doxorubicin, and rituximab) in untreated aggressive diffuse large B-cell lymphoma with MYC rearrangement: a prospective, multicentre, single-arm phase 2 study.

Dunleavy K, Fanale MA, Abramson JS, Noy A, Caimi PF, Pittaluga S, Parekh S, Lacasce A, Hayslip JW, Jagadeesh D, Nagpal S, Lechowicz MJ, Gaur R, Lucas A, Melani C, Roschewski M, Steinberg SM, Jaffe ES, Kahl B, Friedberg JW, Little RF, Bartlett NL, Wilson WH.

Lancet Haematol. 2018 Dec;5(12):e609-e617. doi: 10.1016/S2352-3026(18)30177-7.

PMID:
30501868
14.

Hair Loss Prevention by a Scalp Cooling Device in Early Breast Cancer Patients: The Poliambulanza Preliminary Experience.

Prochilo T, Huscher A, Andreis F, Mirandola M, Zaina E, Pomentale B, Pedrali C, Zanotti L, Mutti S, Zaniboni A.

Rev Recent Clin Trials. 2019;14(1):66-71. doi: 10.2174/1574887113666181120111104.

PMID:
30457055
15.

Non-pegylated liposomal doxorubicin (NPLD, Myocet®) + carboplatin in patients with platinum sensitive ovarian cancers: A ARCAGY-GINECO phase IB-II trial.

Romeo C, Joly F, Ray-Coquard I, El Kouri C, Mercier-Blas A, Berton-Rigaud D, Kalbacher E, Cojocarasu O, Fabbro M, Cretin J, Zannetti A, Abadie-Lacourtoisie S, Mollon D, Hardy-Bessard AC, Provansal M, Blot E, Delbaldo C, Lesoin A, Freyer G, You B.

Gynecol Oncol. 2019 Jan;152(1):68-75. doi: 10.1016/j.ygyno.2018.10.043. Epub 2018 Nov 14.

PMID:
30446275
16.

Clinical impact of prognostic nutritional index in diffuse large B cell lymphoma.

Go SI, Park S, Kang MH, Kim HG, Kim HR, Lee GW.

Ann Hematol. 2019 Feb;98(2):401-411. doi: 10.1007/s00277-018-3540-1. Epub 2018 Nov 9.

PMID:
30413902
17.

Outcomes after R-CHOP in patients with newly diagnosed advanced follicular lymphoma: a 10-year follow-up analysis of the JCOG0203 trial.

Watanabe T, Tobinai K, Wakabayashi M, Morishima Y, Kobayashi H, Kinoshita T, Suzuki T, Yamaguchi M, Ando K, Ogura M, Taniwaki M, Uike N, Yoshino T, Nawano S, Terauchi T, Hotta T, Nagai H, Tsukasaki K; JCOG0203 Collaborators.

Lancet Haematol. 2018 Nov;5(11):e520-e531. doi: 10.1016/S2352-3026(18)30155-8.

PMID:
30389034
18.

Cost-effectiveness of brentuximab vedotin plus chemotherapy as frontline treatment of stage III or IV classical Hodgkin lymphoma.

Delea TE, Sharma A, Grossman A, Eichten C, Fenton K, Josephson N, Richhariya A, Moskowitz AJ.

J Med Econ. 2019 Feb;22(2):117-130. doi: 10.1080/13696998.2018.1542599. Epub 2018 Dec 10.

PMID:
30375910
19.

ATLANTIS: a Phase III study of lurbinectedin/doxorubicin versus topotecan or cyclophosphamide/doxorubicin/vincristine in patients with small-cell lung cancer who have failed one prior platinum-containing line.

Farago AF, Drapkin BJ, Lopez-Vilarino de Ramos JA, Galmarini CM, Núñez R, Kahatt C, Paz-Ares L.

Future Oncol. 2019 Jan;15(3):231-239. doi: 10.2217/fon-2018-0597. Epub 2018 Oct 26.

PMID:
30362375
20.

LONG-TERM RESULTS OF COMBINATION THERAPY FOR LOCALLY ADVANCED BREAST CANCER.

Zhumakayeva A, Rakhimov K, Sirota V, Arystan L, Madiyarov A, Adekenov S.

Georgian Med News. 2018 Sep;(282):30-35.

PMID:
30358536

Supplemental Content

Loading ...
Support Center